Full Access
Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B
PIER MANNUCCIO MANNUCCI,
PIER MANNUCCIO MANNUCCI
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre (WHO Collaborating Centre), IRCCS Maggiore Hospital and University of Milan, Italy
Search for more papers by this authorPIER MANNUCCIO MANNUCCI,
PIER MANNUCCIO MANNUCCI
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre (WHO Collaborating Centre), IRCCS Maggiore Hospital and University of Milan, Italy
Search for more papers by this author
References
- 1 Fletcher ML., Trowell JM., Craske J., Pavier K., Rizza CR.. Non-A, non-B hepatitis after transfusion of factor VIII in unfrequently treated patients. Brit Med J, 1982; 287: 1754–1757.
- 2 Kernoff PBA., Lee CA., Karayanis P., Thomas HC.. High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Brit J Haemat 1985; 60: 469–479.
- 3 Goedert JJ., Kessler CM., Aledort LM., Biggar RJ., Abe Andes, W., White GC., et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med, 1989; 321: 1141–1148.
- 4 Schimpf K., Mannucci PM., Kreuz W., Brackmann HH., Auerswald G., Ciavarella N., et al. Absence of hepatitis after treatment with a pasteurized factor VII. N Engl J Med, 1987; 316: 918–922.
- 5 Mannucci PM., Colombo M.. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis. Thromb Haemostas, 1989; 62: 532–534.
- 6
Colombo M.,
Mannucci PM.,
Carnelli V.,
Savidge GF.,
Schimpf K..
Non-A, non-B hepatitis by heat-treated factor VIII concentrates.
Lancet, 1985; ii: 1–6.
10.1016/S0140-6736(85)90055-8 Google Scholar
- 7 Allain JP., Gazangel C., Sultan Y., Verroust F., and the French Hemophilia Study Group. Clinical evaluation of a heat-treated high purity factor VIII concentrate. (Abstract). Res Clin Lab, 1986; 16: 245.
- 8 Preston FE., Hay CRM., Dewar MS., Greaves M., Triger DR.. Non-A, non-B hepatitis and heat-treated factor VIII concentrates. (Letter). Lancet, 1985; ii: 213.
- 9 Lush CJ., Chapman CS., Mitchell VE., Martin C.. Transmission of hepatitis B by dry-heat treated factor VIII and IX concentrates. Brit J Haemat 1988; 69: 421–428.
- 10 Blanchette VS., Vorstman E., Shore A., Wang E., Petric M., Jett BW., Alter H.. Hepatitis C infection in children with hemophilia A and B. Blood, 1991; 78: 285–289.
- 11 Pistello M., Leccherini-Nelli L., Cecconi N., Bendinelli M., Panicucci F.. Hepatitis C virus prevalence in Italian hemophiliacs infected with virus-inactivated concentrates: 5-year follow-up and correlation with antibodies to other viruses. J Med Virol, 1991; 33: 43–46.
- 12
White GC.,
Matthews TJ.,
Weinhold KJ.,
Hegues BT.,
Cromartie HL.,
McMillan CW.,
Bolognesi DP..
HTLV-III seroconversion associated with heat-treated factor VIII concentrate. (Letter).
Lancet, 1986; i: 611–612.
10.1016/S0140-6736(86)92828-X Google Scholar
- 13
van den Berg W.,
ten Cate JW.,
Breederveld G.,
Goudsmit J..
Seroconversion to HTLV-III in a hemophiliac given heat-treated factor VIII concentrate. (Letter).
Lancet, 1986; i: 803–804.
10.1016/S0140-6736(86)91814-3 Google Scholar
- 14 Mariani G., Ghirardini A., Mandelli F., Verani P., Buttò S., Rossi GB., Mannucci PM.. Heated clotting factor and seroconversion for human immunodeficiency virus in three hemophilic patients. (Letter). Ann Intern Med, 1987; 107: 113.
- 15 Weisser J.. Transmission of the human immunodeficiency virus by a dry heat-treated factor VIII concentrate. Klin Pediatr, 1988; 200: 375–379.
- 16 Dietrich SL., Mosley JW., Lusher JM., Hilgartner MW., Operskalski EA., Habel L., et al. The Transfusion Safety Study Group. Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Vox Sang, 1990; 59: 129–135.
- 17 Remis RJ., O'Shaughnessy MV., Tsoukas C., Growe GH., Schechter MT., Palmer RWH., Lawrence DN.. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrated. Can Med Assoc J 1990; 142: 1247–1254.
- 18 Williams MD., Skidmore SJ., Hill FGH.. HIV seroconversion in hemophilic boys receiving heat-treated factor VIII concentrate. Vox Sang 1990; 58: 135–136.
- 19 Study Group of the UK Haemophiliac Centre Directors Effect of dry-heating of coagulation factor concentrates at 80°C for 72 hours on transmission of non-A, non-B hepatitis. Lancet, 1988; ii: 814–816.
- 20 Skidmore SJ., Pasi KJ., Mawson SJ., Williams MD., Hill FGH.. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med Virol, 1990; 30: 50–52.
- 21 Bennett B., Dawson AA., Gibson BS., Hepplestone A., Lowe GOD., Ludlam CA., et al. Study of viral safety of Scottish National Blood Transfusion Service factor VIII/IX concentrate. Transfusion Med, 1993; 3: 295–298.
- 22 Schimpf K., Brackmann HH., Kreuz W., Kraus B., Haschke F., Schramm W., et al. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A and B or von Willebrand's disease with pasteurized factor VIII concentrate. N Engl J Med, 1989; 321: 1148–1152.
- 23 Mannucci PM., Schimpf K., Brettler DB., Ciavarella N., Colombo M., Haschke F., et al. and the International Study Group. Low risk for hepatitis in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Intern Med, 1990; 113: 27–32.
- 24 Azzi A., Ciappi S., Zakvrezeska K., Morfini M., Mariani G., Mannucci PM.. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity virally attenuated factor VIII concentrates. Am J Hemat, 1992; 39: 228–230.
- 25 Kreuz W., Auerswald G., Bruckmann C., Zieger B., Linde R., Funk M., et al. Prevention of hepatitis C virus infection in children with hemophilia A and B and von Willebrand's disease. (Letter). Thrombos Haemostas, 1992; 67: 184.
- 26 Brackmann HH., Egli H.. Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate. (Letter). Lancet, 1988; ii: 967.
- 27 Schulman S., Lindgren A.Ch., Petrini P., Allander T.. Transmission of hepatitis C with pasteurized factor VIII. (Letter). Lancet, 1992; ii: 305–306.
- 28 Gerritzen A., Schneweis KE., Scholt B., Brackmann HH., Kaiser R., Oldenburg J.. Acute hepatitis C in hemophiliacs due to virus-inactivated clotting factor concentrates. (Letter). Thrombos Haemostas, 1992; 68: 781.
- 29 Kernoff PBA., Miller EJ., Savidge GF., Machin SJ., Dewar MS., Preston FE.. Reduced risk of non-A, non-B hepatitis after first exposure to ‘’wet heated’ factor VIII concentrate. Brit J Haemat, 1987; 67: 207–211.
- 30 Carnelli V., Gomperts ED., Friedman A.. Assessment for evidence of non-A, non-B hepatitis in patients given nheptance suspended heat-treated clotting factor concentrates. Thrombos Res, 1987; 46: 827–834.
- 31
Horowitz MS.,
Rooks C.,
Horowitz B.,
Hilgartner M..
Virus safety of solvent-detergent treated antihemophilic factor concentrate.
Lancet, 1988; ii: 186–189.
10.1016/S0140-6736(88)92288-X Google Scholar
- 32 Gazengel C., Torcher MF., and the French Hemophilia Study Group. Viral safety of solvent/detergent treated FVIII concentrate. (Abstract). Results of a French multicenter study. 18th International Congress of the World Federation of Hemophilia, Madrid, May 26–31, 1988, Abstract book, p. 59.
- 33 Noel L., Guerois C., Maisonneuve P., Verroust F., Laurian Y.. Antibodies to hepatitis C virus in hemophilia. (Letter). Lancet, 1989; ii: 560.
- 34 Gonzaga AL., Boneker C.. Follow-up of hemophiliacs using solvent/detergent treated FVIII and FIX concentrates. (Abstract). 19th International Congress of the World Federation of Hemophilia, Washington, August 1419, 1990, Abstract book, p. 25.
- 35 Mariani G., Di Paolantonio T., Baklaya R., Morfini M., Mannucci PM., and the Ad Hoc Study Group of the Fondazione dell'Emofilia. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped virus. Transfusion, 1993; 33: 814–818.
- 36 Addiego JE., Gomperts E., Shu-Leu Liu., Bailey P., Courter SG., Lee ML., et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIC immunoaffinity chromatography. Thrombos Haemostas, 1992; 67: 19–27.
- 37 Dipaolantonio T., Mariani G., Ghirardini A., Gringeri A., Mannucci PM., Mastrullo L., et al. Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate. J Med Virol, 1992; 36: 71–74.
- 38 Mannucci PM.. Outbreak of hepatitis A among Italian patients with hemophilia. (Letter). Lancet, 1992; i: 819.
- 39 Gerritzen A., Schneweis KE., Brackmann HH., et al Acute hepatitis A in hemophiliacs. (Letter). Lancet, 1992; 340: 1231–1232.
- 40 Temperley IJ., Cotter KP., Walsh TJ., Power J., Hillary IB.. Clotting factors and hepatitis A. (Letter). Lancet, 1992; 340: 1466.
- 41 Peerlinck K., Vermylen J.. Acute hepatitis A in patients with hemophilia A. (Letter). Lancet, 1993; 341: 189.
- 42 Mannucci PM., Zanetti AR., Colombo M.. Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Brit J Haemat, 1988; 68: 427–430.
- 43 Mannucci PM., Zanetti AR., Colombo M., Chistolini A., De Biasi R., Musso R., Tamponi G.. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia. Thrombos Haemostas, 1990; 64: 232–234.
- 44 Mannucci PM., Schimpf K., Abe T., Aledort LM., Anderle K., Brettler DB., Hilgartner MW., et al., and the International Study Group. Low risk of viral infection after administration of vapour heated factor VIII concentrates. Transfusion, 1992; 32: 134–138.
- 45 Shapiro A., and the International Factor Safety Study Group. A study to determine the safety of virus inactivated factor concentrates in hemophiliacs naive to blood product administration: factor VII concentrate (human) Immuno, vapour heated and factor IX complex (human) Immuno, vapour heated. (Abstract). 20th International Congress of the World Federation of Hemophilia, Athens, October 1217, 1992. Abstract book, p. 25.
- 46 Klein JP., Bailly E., Schneweis KE., Brackmann HH., Hammerstein U., Haufland P., et al. Acute HIV-1 infection in patients with hemophilia B treated with beta-propiolactone UV-inactivated clotting factor. (Letter). Thrombos Haemostas, 1990; 64: 336–337.
- 47 Rubinstein AI., Rubinstein DB., Coughlin J.. Combined solvent/detergent and 100°C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility. (Letter). Vox Sang 1991; 60: 60.
- 48 Santagostino E., Mannucci PM., Gringeri A., Azzi A., Morfini M.. Eliminating parvovirus B19 from blood products. (Letter). Lancet, 1994; 343: 798.
- 49 Risks associated with human parvovirus B19 infection. MMWR, 1989; 38: 81–83.
- 50 Kim HC., McMillan CW., White GC., Bergman GE., Horton MW., Saidi P.. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood, 1992; 79: 568–575.
- 51 Burnouf-Radosevich M., Appourchaux P., Huart JJ., Burnouf T.. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang, 1994:in press.
- 52 Horowitz B., Bonomo R., Prince AM., Chin SN., Brotoman B., Shulman RW.. Solvent/detergent treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood, 1992; 79: 826–831.
- 53 Mohr H., Lambrecht B., Kruver-Hoff J.. Virus inactivated single donor fresh plasma preparations. (Abstract). Infusionstherapie, 1991; 18 (Suppl. 2): 71.
- 54 Burnouf-Radosevich M., Burnouf T., Huart JJ.. A pasteurized therapeutic plasma. Infusionstherapie, 1992; 19: 91–94.
- 55 Smit-Sibinga C., Schulting PJ., Noteboner J., Das PC., Marriunk J., van den Meer, J.. Double cryoprecipitated factor VIII concentrate from heparinized plasma and its heat treatment. Blut, 1988; 56: 111–116.
- 56 Peerlinck K., Rosendaal FR., Vermylen J.. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood, 1993; 81: 3332–3335.
Citing Literature
